Health systems/plans share common coverage vision for Clarinex, OTC Claritin

News
Article

Last month the FDA's Nonprescription Drugs Advisory Committee unanimously supported loratadine's (Claritin, Schering-Plough) switch from prescription to over-the-counter status for treatment of chronic idiopathic urticaria, moving the drug one step closer to full OTC status (see significant event timeline in sidebar).

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.